This qualitative study explores the experience of hepatitis C virus treatment for people with pre-existing mental health problems within a large city hospital. Four men and four women with pre-existing mental health problems who had received hepatitis C virus treatment took part in semi-structured interviews which were analysed using interpretative phenomenological analysis. A central theme of ‘Self, stigma and change’ was identified which interlinked with three other main themes of ‘Coping and responding to treatment’, ‘Connectedness to others’ and ‘The impact of information’. These themes and their sub-themes are discussed in relation to existing literature and clinical practice guidelines.
BirchwoodM (1996) Early intervention in psychotic relapse: Cognitive approaches to detection and relapse. In: HaddockGSladePD (eds) Cognitive Behavioural Interventions with Psychotic Disorders. London: Routledge, pp. 171–211.
2.
BoothJCLO’GradyJNeubergerJ (2001) Clinical guidelines on the management of hepatitis C. Gut49: 1–21.
3.
ChainuvatiSKhalidSKKancirS. (2006) Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. Journal of Viral Hepatitis13: 235–241.
4.
ClandininJConnellyFM (2000) Narrative Inquiry: Experience and Story in Qualitative Research. San Francisco, CA: Jossey-Bass Publishers, pp. 98–115. Available at: http://en.wikipedia.org/wiki/Narrative_inquiry
5.
CroneCCGabrielGM (2003) Comprehensive review of hepatitis c for psychiatrists: Risks, screening, diagnosis, treatment, and interferon-based therapy complications. Journal of Psychiatric Practice9: 93–110.
6.
Department of Health. (2004) Hepatitis C action plan for England. London: Department of Health.
7.
DieperinkEHoSBThrasP. (2003) A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis c. Psychosomatics44: 104–112.
8.
DoreG (2001) Therapy decision making for people with chronic hepatitis C. In: CroftsNDoreGLocarniniS (eds) Hepatitis C: An Australian Perspective. Melbourne, VIC, Australia: IP Communications, 172–182.
9.
ElliottRFischerCTRennieDL (1999) Evolving guidelines for the publication of qualitative research studies in psychology and related fields. British Journal of Clinical Psychology38: 215–229.
10.
FattovichGGiustinaGFavaratoS. (1996) A survey of adverse events in 11,241 patients with chronic viral hepatitis C treated with alpha interferon. Journal of Hepatology24: 38–47.
11.
GlackenMCoatesVKernohianG. (2003) The experience of fatigue for people living with hepatitis C. Journal of Clinical Nursing12: 244–252.
12.
GlackenMKernohianGCoatesV (2001) Diagnosed with hepatitis C: A descriptive-exploratory study. International Journal of Nursing Studies38: 107–116.
13.
GlaserBGStraussA (1967) The Discovery of Grounded Theory: Strategies for Qualitative Research. Chicago, IL: Aldine.
14.
GoldenJConroyRMO’DwyerAM. (2006) Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Social Science & Medicine63: 3188–3198.
Health Protection Agency (HPA) (2011) ‘Shooting Up’ Report. London: Health Protection Agency, Centre for Infections.
17.
HopwoodMSouthgateE (2003) Living with hepatitis C: A sociological review. Critical Public Health13(3): 251–267.
18.
HopwoodMTreloarC (2005) The experience of interferon-based treatments for hepatitis C infection. Qualitative Health Research15: 635–646.
19.
HopwoodMTreloarC (2011) Resilient coping: Applying adaptive responses to prior adversity during treatment for hepatitis C infection. Journal of Health Psychology13(1): 17–27.
20.
IancuISverdlikADannonP. (1997) Bipolar disorder associated with interferon-alpha treatment. Postgraduate Medical Journal73: 834–835.
JanssenHLBrouwerJTvan der MastRC. (1994) Suicide associated with alpha-interferon therapy for chronic viral hepatitis. Journal of Hepatology21: 241–243.
23.
JonesEEFarinaAHastorfA. (1984) Social Stigma – The Psychology of Marked Relationships. New York: Freeman.
24.
LarkinMGriffithsMD (2002) Experiences of addiction and recovery: The case for subjective accounts. Addiction Research & Theory10(3): 281–311.
25.
LeventhalHNerenzDRSteeleDF (1984) Illness representations and coping with health threats. BaumATaylorSESingerJE (eds) A Handbook of Psychology and Health. Hillsdale, NJ: Erlbaum, 219–252.
26.
LinkBGPhelanJC (2006) Stigma and its public health implications. Lancet367(9509): 528–529.
27.
LobbanFBarrowcloughCJonesS (2003) A review of the role of illness models in severe mental illness. Clinical Psychology Review23: 171–196.
28.
MacLeanLMMeyerMEstableA (2004) Improving accuracy of transcripts in qualitative research. Qualitative Health Research14: 113–123.
29.
MannsMPMcHutchinsonJGGordonSC. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon-alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet358: 958–965.
30.
National Institute for Health and Clinical Excellence (NICE) (2004) Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance 75, January2004.
31.
National Institute for Health and Clinical Excellence (NICE) (2006) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. NICE technology appraisal guidance 106, August2006.
32.
National Institute for Health and Clinical Excellence (NICE) (2010) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part review of NICE technology appraisal guidance 75 and 106). NICE technology appraisal guidance 200, September2010.
33.
National Institute for Health and Clinical Excellence (NICE) (2012a) Boceprevir for the treatment of genotype 1 chronic hepatitis C. NICE technology appraisal guidance 253, April. London: NICE.
34.
National Institute for Health and Clinical Excellence (NICE) (2012b) Telaprevir for the treatment of genotype 1 chronic hepatitis C. NICE technology appraisal guidance 252, April. Available at: http://guidance.nice.org.uk/TA252/Guidance/pdf/English
35.
National Institutes of Health (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 – June 10–12, 2002. Hepatology36(5): 3–20.
36.
PollR (2012a) Hepatitis C part 1: Detection and assessment. Practice Nursing23(8): 396–400.
37.
PollR (2012b) Hepatitis C part 2: Treatment and prevention. Practice Nursing23(11): 540–546.
38.
PotterJWetherellM (1987) Discourse and social psychology: Beyond attitudes and behaviour. London: Sage.
39.
RotterJB (1966) Generalised expectancies for internal and external control of reinforcement. Psychological Monographs: General and Applied80: 1–28.
40.
Royal College of General Practitioners (2007) Guidance for the Prevention, Testing, Treatment and Management of Hepatitis C in Primary Care. London: Royal College of General Practitioners.
41.
SchaeferMEngelbrechtMAGutO. (2002) Interferon alpha (IFNα) and psychiatric syndromes: A review. Progress in Neuro-Psychopharmacology and Biological Psychiatry26: 731–746.
42.
SchaeferMSchmidtFFolwacznyC. (2003) Adherence and mental side effects during Hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology37: 443–451.
43.
SchmidtSDBlankTOBellizziKM. (2012) The relationship of coping strategies, social support, and attachment style with post traumatic growth in cancer survivors. Journal of Health Psychology17(7): 1033–1040.
44.
SmithJA (1995) Semi-structured interviewing and qualitative analysis. In: SmithJHarreRVan LangenhoveL (eds) Rethinking Methods in Psychology. London: SAGE, 9–26.
45.
SmithJAJarmanMOsbornM (1999) Doing interpretative phenomenological analysis. In: MurrayMChamberlaiK (eds) Qualitative Health Psychology: Theories and Methods. London: SAGE, pp. 218–241.
46.
SockalingamSLinksPSAbbeySE (2011) Suicide risk in hepatitis C and during interferon-alpha therapy: A review and clinical update. Journal of Viral Hepatitis18(3): 153–160.
47.
SylvestreDLLitwinAHClementsBJ. (2004) The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment29: 159–165.
48.
University of Sheffield (2008) Transcriber’s Information Sheet and Confidentiality Declaration. Sheffield: Department of Clinical Psychology, University of Sheffield.
49.
YardleyL (2000) Dilemmas in qualitative health research. Psychology & Health15: 215–228.
50.
ZdilarDFranco-BronsonKBuchlerN. (2000) Hepatitis C, interferon alpha, and depression. Hepatology31: 1207–1211.
51.
ZickmundSHoEYMasudaM. (2003) ‘They treated me like a leper’: Stigmatization and the quality of life of patients with hepatitis C. Journal of General Internal Medicine18: 835–844.
